Replies to post #345 on Vascular Biogenics Ltd (VBLT)

[gr8db8]

FDA reviews and verifies the data and will not approve a trial for a number of reasons, including improper (selective) censoring.

The shorts complained about rGBM data and said there was no way it would move to phase 3.